References

ASR Joint Regen Review

Arthritis Causes and Treatment

Get Instant Access

1. Symmons D, Asten P, McNally R, Webb R. Healthcare needs assessment for musculoskeletal diseases. Arthritis Research Campaign Epidemiology Unit, University of Manchester 2002. Available from: URL: www.arc.org.uk

2. Churchill R, Allen J, Denman S, Williams D, Fielding K, von FM. Do the attitudes and beliefs of young teenagers towards general practice influence actual consultation behaviour? Br J Gen Pract 2000; 50(461):953-7.

Adam V, St-Pierre Y, Fautrel B, Clarke AE, Duffy CM, Penrod JR. What is the impact of adolescent arthritis and rheumatism? Evidence from a national sample of Canadians. J Rheumatol 2005; 32(2):354-61. Thomson W, Barrett JH, Donn R, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford) 2002; 41(10):1183-9.

McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 1995; 38(9):1260-70.

Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34(8):732-6. Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49(3): 300-5.

Medsger TA Jr, Dawson WN Jr, Masi AT. The epidemiology of polymyositis. Am J Med 1970; 48(6):715-23.

Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin N Am 2002; 28(4):833-57.

Britto MT, DeVellis RF, Hornung RW, DeFriese GH, Atherton HD, Slap GB. Health care preferences and priorities of adolescents with chronic illnesses. Pediatrics 2004; 114(5):1272-80.

Zeek PM. Periarteritis nodosa; a critical review. Am J Clin Pathol 1952; 22(8): 777-90.

Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990; 33(8):1065-7.

Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2):187-92.

Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123(3):192-4.

Weyand CM, Goronzy JJ. Molecular approaches toward pathologic mechanisms in giant cell arteritis and Takayasu's arteritis. Curr Opin Rheumatol 1995; 7(1):30-6.

Michet CJ. Epidemiology of vasculitis. Rheum Dis Clin N Am 1990; 16(2): 261-8.

Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics 1995; 95(4):475-9.

Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360(9341):1197-202. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996; 39(1):87-92.

20. Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995; 25(1): 28-34.

21. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33(8):1129-34.

22. Lindsley CB. Takayasu's arteritis. In: Cassidy J, Petty R, eds. Textbook of Pediatric Rheumatology. 4th ed. philadelphia: WB Saunders, 2001:614-5.

23. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore) 1985; 64(2):89-99.

24. Morales E, Pineda C, Martinez-Lavin M. Takayasu's arteritis in children. J Rheumatol 1991; 18(7):1081-4.

25. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994; 120(11):919-29.

26. Hoffman GS. Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol 1996; 54(Suppl.):S99-102.

27. Vanoli M, Daina E, Salvarani C, et al. Takayasu's arteritis: A study of 104 Italian patients. Arthritis Rheum 2005; 53(1):100-7.

28. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37(4):578-82.

29. Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS. Takayasu's arteritis and its therapy. Ann Intern Med 1985; 103(1):121-6.

30. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114(6):1708-33.

31. Lightfoot RW, Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33(8):1088-93.

32. Ewald EA, Griffin D, McCune WJ. Correlation of angiographic abnormalities with disease manifestations and disease severity in polyarteritis nodosa. J Rheumatol 1987; 14(5):952-6.

33. Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med 1967; 43(1):8-14.

34. Dillon MJ, Ansell BM. Vasculitis in children and adolescents. Rheum Dis Clin N Am 1995; 21(4):1115-36.

35. Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin N Am 1995; 21(4):911-47.

36. Rottem M, Fauci AS, Hallahan CW, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122(1):26-31.

37. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335(1):16-20.

38. Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N. Group A streptococcal antigen in the glomeruli of children with Henoch-Schonlein nephritis. Am J Kidney Dis 2003; 41(2):366-70.

39. Giangiacomo J, Tsai CC. Dermal and glomerular deposition of IgA in anaphylactoid purpura. Am J Dis Child 1977; 131(9):981-3.

40. Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schonlein purpura in an unselected childhood population. Eur J Pediatr 1988; 147(2):113-5.

41. Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet 1992; 339(8788):280-2.

42. Pattishall EN, Strope GL, Spinola SM, Denny FW. Childhood sarcoidosis. J Pediatr 1986; 108(2):169-77.

43. Sarica R, Azizlerli G, Kose A, Disci R, Ovul C, Kural Z. Juvenile Behcet's disease among 1784 Turkish Behcet's patients. Int J Dermatol 1996; 35(2): 109-11.

44. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990; 335(8697):1078-80.

45. Pachman LM, Cooke N. Juvenile dermatomyositis: a clinical and immuno-logic study. J Pediatr 1980; 96(2):226-34.

46. Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17(10):1329-34.

47. Hanissian AS, Masi AT, Pitner SE, Cape CC, Medsger TA Jr. Polymyositis and dermatomyositis in children: an epidemiologic and clinical comparative analysis. J Rheumatol 1982; 9(3):390-4.

48. Hiketa T, Ohashi M. Juvenile dermatomyositis - statistical observation of 105 patients with dermatomyositis. Nippon Hifuka Gakkai Zasshi 1991; 101(8): 825-30.

49. Shehata R, al-Mayouf S, al-Dalaan A, al-Mazaid A, al-Balaa S, Bahabri S. Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol 1999; 17(1):115-8.

50. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25(6): 1198-204.

51. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56(4):255-86.

52. Rider LG, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14(1):37-54.

53. Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Deramtomyositis. J Pediatr 1964; 64:101-31.

54. Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999; 78(3): 139-47.

55. Sallum AM, Kiss MH, Sachetti S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 2002; 60(4):889-99.

56. Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr 1984; 105(3):399-408.

57. Muller SA, Winkelmann RK, Brunsting LA. Calcinosis in dermatomyositis; observations on course of disease in children and adults. AMA Arch Derm 1959; 79(6):669-73.

58. Banker BQ, Victor M. Dermatomyositis (systemic angiopathy) of childhood. Medicine (Baltimore) 1966; 45(4):261-89.

59. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292(7):344-7.

60. Martini G, Calabrese F, Biscaro F, Zulian F. A child with dermatomyositis and a suspicious lymphadenopathy. J Rheumatol 2005; 32(4):744-6.

61. Sherry DD, Haas JE, Milstein JM. Childhood polymyositis as a paraneoplastic phenomenon. Pediatr Neurol 1993; 9(2):155-6.

62. Falcini F, Taccetti G, Trapani S, Lippi A, Bartolozzi G. Acute lymphocytic leukemia with dermatomyositis-like onset in childhood. J Rheumatol 1993; 20(7):1260-2.

63. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermato-myositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 2002; 41(11):729-34.

64. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357(9250):96-100.

65. Huber AM, Lang B, LeBlanc CM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43(3):541-9.

66. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002; 41(1):22-6.

67. Maillard SM, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004; 43(5):603-8.

68. Hernandez RJ, Sullivan DB, Chenevert TL, Keim DR. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol 1993; 161(2):359-66.

69. Brown V, Halkon E, Pilkington C, et al. Revision of diagnostic criteria for juvenile dermatomyositis [abstract]. Clin Exp Rheumatol 2004; 22:528.

70. Pitt AM, Fleckenstein JL, Greenlee RG Jr, Burns DK, Bryan WW, Haller R. MRI-guided biopsy in inflammatory myopathy: initial results. Magn Reson Imaging 1993; 11(8):1093-9.

Chung YL, Wassif WS, Bell JD, Hurley M, Scott DL. Urinary levels of creatine and other metabolites in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2003; 42(2):298-303. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31(8):1644-9.

Rider LG, Feldman BM, Perez MD, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997; 40(11):1976-83.

Miller LC, Michael AF, Baxter TL, Kim Y. Quantitative muscle testing in childhood dermatomyositis. Arch Phys Med Rehabil 1988; 69(8):610-3. Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999; 42(10):2213-9.

Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50(5):1595-603.

Takken T, Elst E, Spermon N, Helders PJ, Prakken AB, van der NJ. The physiological and physical determinants of functional ability measures in children with juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42(4): 591-5.

Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996; 23(10):1794-7.

Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47(4):505-11. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24(12):2436-43. Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1(8646):1063-6.

Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989; 16(12):1545-7.

Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27(10):2498-503.

Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. Arch Neurol 1981; 38(9):544-52.

Anderson L, Ziter FA. Plasmapheresis via central catheter in dermatomyositis: a new method for selected pediatric patients. J Pediatr 1981; 98(2):240-1.

86. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004; 43(4):491—6.

87. Maillard S, Wilkinson N, Beresford MW, Davidson JE, Murray KJ. The treatment of persistent severe idiopathic inflammatory myositis with anti-TNF therapy. [abstract]. Arthritis Rheum 2002; 44:S307.

88. Levine TD. A pilot study of rituximab therapy for refractory dermatomyositis. [abstract]. Arthritis Rheum 2002; 46:S488.

89. Maillard SM, Jones R, Owens CM, et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 2005; 53(4):558-64.

90. Sullivan DB, Cassidy JT, Petty RE. Dermatomyositis in the pediatric patient. Arthritis Rheum 1977; 20(Suppl. 2):327-31.

91. Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr (Phila) 1987; 26(11):561-6.

92. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103(6):882-8.

93. Alsufyani KA, Ortiz-Alvarez O, Cabral DA, et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005; 32(4):729-33.

94. Vancheeswaran R, Black CM, David J, et al. Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum 1996; 39(6):1041-9.

95. Murray KJ, Laxer RM. Scleroderma in children and adolescents. Rheum Dis Clin N Am 2002; 28(3):603-24.

96. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997; 24(1):73-80.

97. Mayes MD. Classification and epidemiology of scleroderma. Semin Cutan Med Surg 1998; 17(1):22-6.

98. Uziel Y, Krafchik BR, Silverman ED, Thorner PS, Laxer RM. Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum 1994; 23(5):328-40.

99. Soma Y, Tamaki T, Kikuchi K, Abe M, Igarashi A, Takehara K, et al. Coexistence of morphea and systemic sclerosis. Dermatology 1993; 186(2): 103-5.

100. Lapiere JC, Aasi S, Cook B, Montalvo A. Successful correction of depressed scars of the forehead secondary to trauma and morphea en coup de sabre by en bloc autologous dermal fat graft. Dermatol Surg 2000; 26(8):793-7.

101. Eguchi T, Harii K, Sugawara Y. Repair of a large "coup de sabre" with soft-tissue expansion and artificial bone graft. Ann Plast Surg 1999; 42(2):207-10.

102. Sengezer M, Deveci M, Selmanpakoglu N. Repair of "coup de sabre," a linear form of scleroderma. Ann Plast Surg 1996; 37(4):428-32.

103. Katarincic JA, Bishop AT, Wood MB. Free tissue transfer in the treatment of linear scleroderma. J Pediatr Orthop 2000; 20(2):255-8.

104. Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997; 40 (3):441-5.

105. Mayes MD, Lacey JV, Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48(8):2246-55.

106. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40(1):84-8.

107. Cozzi F, Marson P, Rosada M, et al. Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity. Transfus Apher Sci 2001; 25(1):25-31.

108. Korn JH, Mayes M, Matucci CM, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50(12):3985-93.

109. Giannelli G, Iannone F, Marinosci F, Lapadula G, Antonaci S. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 2005; 21(3): 327-32.

110. Foeldvari I, Zhavania M, Birdi N, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford) 2000; 39(5):556-9.

111. Waagner DC. Musculoskeletal infections in adolescents. Adolesc Med 2000; 11(2):375-400.

112. Hashkes PJ, Biro F, Glass D. Infection, arthritis and adolescence. In: Isenberg DA, Miller J, eds. Adolescent Rheumatology. 1st ed. London: Martin Dunitz; 2005:45-70.

113. Cassidy JT, Petty RE. Arthritis Related to Infection. Textbook of Pediatric Rheumatology. 4th ed. Philadelphia: Saunders; 2001:640-711.

114. Jurik AG. Chronic recurrent multifocal osteomyelitis. Semin Musculoskelet Radiol 2004; 8(3):243-53.

115. Girschick HJ, Raab P, Surbaum S, et al. Chronic non-bacterial osteomyelitis in children. Ann Rheum Dis 2005; 64(2):279-85.

116. Kerrison C, Davidson JE, Cleary AG, Beresford MW. Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology (Oxford) 2004; 43(10):1246-51.

117. Buller HA. Problems in diagnosis of IBD in children. Neth J Med 1997; 50(2): S8-11.

118. McDonagh J. Juvenile spondyloarthropathies and other causes of back pain. In: Isenberg DA, Miller J, eds. Adolescent Rheumatology. 1st ed. London: Martin Dunitz, 1999:99.

119. Petty RE, Cassidy JT. Arthropathies of inflammatory bowel disease. In: Cassidy JT, Petty RE, eds. Textbook of Pediatric Rheumatology. 4th ed. Philadelphia: WB Saunders, 2001:357-61.

120. Cassidy J, Petty R. Primary and Acquired Disorders of Bone and Connective Tissue. Textbook of Pediatric Rheumatology. 4th ed. Philadelphia: WB Saunders, 2001:726-54.

121. Leeson MC, Makley JT, Carter JR. Metastatic skeletal disease in the pediatric population. J Pediatr Orthop 1985; 5(3):261-7.

122. Cassidy JT, Petty RE. Skeletal malignancies and related disorders. In: Cassidy JT, Petty RE, eds. Textbook of Pediatric Rheumatology. 4th ed. Philadelphia: WB Saunders, 2001:763-78.

123. Bacci G, Longhi A, Bertoni F, et al. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J Pediatr Hematol Oncol 2005; 27(3):129-34.

124. McDermott MF, Frenkel J. Hereditary periodic fever syndromes. Neth J Med 2001; 59(3):118-25.

125. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81(5):349-68.

126. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998; 351 (9103):659-64.

127. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004; 43(8):698-704.

Was this article helpful?

0 0
Natural Arthritis Relief

Natural Arthritis Relief

Natural Arthritis Relief details a unique method of reversing Rheumatoid Arthritis Symptoms by removing numerous arthritis triggers as well as toxins using a simple 5 step natural process.

Get My Free Ebook


Post a comment